PDS Biotechnology (PDSB) Restructuring Costs (2018 - 2026)
PDS Biotechnology's (PDSB) quarterly Restructuring Costs came in at $359149.0 in Q4 2025, up 4.35% YoY from $344185.0 in Q4 2024, and down 0.66% on a QoQ basis from $361546.0 in Q3 2025.
PDS Biotechnology (PDSB) Restructuring Costs (2018 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 3 years of Restructuring Costs data on file, last reported at $359149.0 in Q4 2025.
- Quarterly Restructuring Costs rose 4.35% year-over-year to $359149.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (up 0.98% YoY) and the FY2025 annual result came in at $1.5 million, up 0.98% from the prior year.
- Restructuring Costs retreated to $359149.0 in Q4 2025, from $361546.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $387897.0 in Q2 2025 to a low of $344185.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | PDS Biotechnology | 11.58 Mn | 11.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 309,370.00 |
| Dec 31, 2025 | 359,149.00 |
| Sep 30, 2025 | 361,546.00 |
| Jun 30, 2025 | 387,897.00 |
| Mar 31, 2025 | 344,354.00 |
| Dec 31, 2024 | 344,185.00 |
| Sep 30, 2024 | 351,081.00 |
| Jun 30, 2024 | 378,905.00 |
| Mar 31, 2024 | 364,662.00 |
| Dec 31, 2018 | 2.42 Mn |
| Sep 30, 2018 | 847,852.00 |
| Jun 30, 2018 | 6.65 Mn |